Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire

BACKGROUND: Neoadjuvant immunotherapy utilizing novel combinations has the potential to transform the standard of care for locally/regionally advanced melanoma. We hypothesized that neoadjuvant ipilimumab in combination with high dose IFNα2b (HDI) is safe and associated with durable pathologic compl...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: Tarhini, Ahmad, Lin, Yan, Lin, Huang, Rahman, Zahra, Vallabhaneni, Priyanka, Mendiratta, Prateek, Pingpank, James F., Holtzman, Matthew P., Yusko, Erik C., Rytlewski, Julie A., Rao, Uma N. M., Ferris, Robert L., Kirkwood, John M.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2018
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6199801/
https://ncbi.nlm.nih.gov/pubmed/30352626
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-018-0428-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados